Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App.
Eastern Cooperative Oncology Group (ECOG)
app
cancer
machine learning
patient-reported outcomes
quality of life
smartphone-based ecological momentary assessment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
02
2022
accepted:
10
06
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
We have defined a project to develop a mobile app that continually records smartphone parameters which may help define the Eastern Cooperative Oncology Group performance status (ECOG-PS) and the health-related quality of life (HRQoL), without interaction with patients or professionals. This project is divided into 3 phases. Here we describe phase 1. The objective of this phase was to develop the app and assess its usability concerning patient characteristics, acceptability, and satisfaction. The app eB2-ECOG was developed and installed in the smartphone of cancer patients who will be followed for six months. Criteria inclusion were: age over 18-year-old; diagnosed with unresectable or metastatic lung cancer, gastrointestinal stromal tumor, sarcoma, or head and neck cancer; under systemic anticancer therapies; and possession of a Smartphone. The app will collect passive and active data from the patients while healthcare professionals will evaluate the ECOG-PS and HRQoL through conventional tools. Acceptability was assessed during the follow-up. Patients answered a satisfaction survey in the app between 3-6 months from their inclusion. The app developed provides a system for continuously collecting, merging, and processing data related to patient's health and physical activity. It provides a transparent capture service based on all the available data of a patient. Currently, 106 patients have been recruited. A total of 36 patients were excluded, most of them (21/36) due to technological reasons. We assessed 69 patients (53 lung cancer, 8 gastrointestinal stromal tumors, 5 sarcomas, and 3 head and neck cancer). Concerning app satisfaction, 70.4% (20/27) of patients found the app intuitive and easy to use, and 51.9% (17/27) of them said that the app helped them to improve and handle their problems better. Overall, 17 out of 27 patients [62.9%] were satisfied with the app, and 14 of them [51.8%] would recommend the app to other patients. We observed that the app's acceptability and satisfaction were good, which is essential for the continuity of the project. In the subsequent phases, we will develop predictive models based on the collected information during this phase. We will validate the method and analyze the sensitivity of the automated results.
Sections du résumé
Background
UNASSIGNED
We have defined a project to develop a mobile app that continually records smartphone parameters which may help define the Eastern Cooperative Oncology Group performance status (ECOG-PS) and the health-related quality of life (HRQoL), without interaction with patients or professionals. This project is divided into 3 phases. Here we describe phase 1. The objective of this phase was to develop the app and assess its usability concerning patient characteristics, acceptability, and satisfaction.
Methods
UNASSIGNED
The app eB2-ECOG was developed and installed in the smartphone of cancer patients who will be followed for six months. Criteria inclusion were: age over 18-year-old; diagnosed with unresectable or metastatic lung cancer, gastrointestinal stromal tumor, sarcoma, or head and neck cancer; under systemic anticancer therapies; and possession of a Smartphone. The app will collect passive and active data from the patients while healthcare professionals will evaluate the ECOG-PS and HRQoL through conventional tools. Acceptability was assessed during the follow-up. Patients answered a satisfaction survey in the app between 3-6 months from their inclusion.
Results
UNASSIGNED
The app developed provides a system for continuously collecting, merging, and processing data related to patient's health and physical activity. It provides a transparent capture service based on all the available data of a patient. Currently, 106 patients have been recruited. A total of 36 patients were excluded, most of them (21/36) due to technological reasons. We assessed 69 patients (53 lung cancer, 8 gastrointestinal stromal tumors, 5 sarcomas, and 3 head and neck cancer). Concerning app satisfaction, 70.4% (20/27) of patients found the app intuitive and easy to use, and 51.9% (17/27) of them said that the app helped them to improve and handle their problems better. Overall, 17 out of 27 patients [62.9%] were satisfied with the app, and 14 of them [51.8%] would recommend the app to other patients.
Conclusions
UNASSIGNED
We observed that the app's acceptability and satisfaction were good, which is essential for the continuity of the project. In the subsequent phases, we will develop predictive models based on the collected information during this phase. We will validate the method and analyze the sensitivity of the automated results.
Identifiants
pubmed: 35936756
doi: 10.3389/fonc.2022.880430
pmc: PMC9351705
doi:
Types de publication
Journal Article
Langues
eng
Pagination
880430Informations de copyright
Copyright © 2022 Escudero-Vilaplana, Romero-Medrano, Villanueva-Bueno, Rodríguez de Diago, Yánez-Montesdeoca, Collado-Borrell, Campaña-Montes, Marzal-Alfaro, Revuelta-Herrero, Calles, Galera, Álvarez, Herranz, Sanjurjo and Artés-Rodríguez.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA Oncol. 2015 Sep;1(6):778-84
pubmed: 26203912
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Expert Opin Drug Saf. 2016;15(4):427-35
pubmed: 26854363
Indian J Palliat Care. 2017 Oct-Dec;23(4):445-450
pubmed: 29123353
Farm Hosp. 2016 Jan 01;40(1):25-35
pubmed: 26882831
J Pain Symptom Manage. 2010 Feb;39(2):250-8
pubmed: 20152588
Med Clin (Barc). 1999;112 Suppl 1:79-85
pubmed: 10618804
Support Care Cancer. 2021 Jan;29(1):7-10
pubmed: 32844316
Eur Respir J. 2016 Sep;48(3):852-60
pubmed: 27390281
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Psychooncology. 2017 Jun;26(6):755-762
pubmed: 26790987
BMJ Open. 2020 Jul 19;10(7):e035041
pubmed: 32690505
Br J Cancer. 2003 Sep 15;89(6):1022-7
pubmed: 12966419
J Clin Sleep Med. 2019 Nov 15;15(11):1645-1653
pubmed: 31739855
Support Care Cancer. 2014 Jan;22(1):181-7
pubmed: 24026981
NPJ Digit Med. 2018 Jul 5;1:27
pubmed: 31304309
J Clin Oncol. 2009 Apr 20;27(12):1948-55
pubmed: 19255311
Rev Esc Enferm USP. 2020 Mar 27;54:e03546
pubmed: 32236346
Int J Environ Res Public Health. 2020 Apr 22;17(8):
pubmed: 32331273
BMC Psychiatry. 2019 Sep 7;19(1):277
pubmed: 31493783
Eur J Cancer. 1993;29A Suppl 1:S51-8
pubmed: 8381294
J Affect Disord. 2020 Sep 1;274:733-741
pubmed: 32664009
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncol Nurs Forum. ;44(1):31-43
pubmed: 28067033
Nat Biotechnol. 2015 May;33(5):462-3
pubmed: 25965751
Support Care Cancer. 1999 Sep;7(5):332-5
pubmed: 10483818
J Oncol. 2016;2016:6186543
pubmed: 27066075
Cancer. 2011 Mar 1;117(5):1038-48
pubmed: 20957722
Front Oncol. 2020 Sep 02;10:1645
pubmed: 32984036
Eur J Cancer Care (Engl). 2019 May;28(3):e13095
pubmed: 31090160
JAMA. 2019 Jan 22;321(3):306-307
pubmed: 30667494
Lung Cancer. 2013 Aug;81(2):288-93
pubmed: 23561304
Anal Bioanal Chem. 2021 Apr;413(9):2389-2406
pubmed: 33586007
Eur J Oncol Nurs. 2021 Feb;50:101897
pubmed: 33476977
J Sleep Res. 2020 Feb;29(1):e12931
pubmed: 31626361
Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):456-467
pubmed: 34048816
Am J Health Syst Pharm. 2020 Aug 20;77(17):1393-1402
pubmed: 32620958